How often does tigecycline raise liver enzymes?
Liver enzyme elevations are a recognized adverse effect of tigecycline, but the exact frequency depends on which liver tests were counted (for example, AST/ALT alone versus “any hepatic abnormality”) and how “elevation” was defined in the study.
Across the clinical experience summarized in drug safety information, liver enzyme increases (including elevations in ALT and AST) are described as occurring in a minority of patients, generally more often than in the placebo/comparator groups. Serious hepatic events are uncommon, and most cases—when they occur—are detected on lab monitoring rather than driven by symptoms.
What counts as “elevation” in clinical studies?
When papers and safety labels report liver enzyme elevation, they often include thresholds like:
- Any increase from baseline above the lab’s upper limit of normal
- Grade 1–3 (mild to moderate) versus grade 4 (marked) elevations
- “Hepatic transaminase elevations” specifically (AST/ALT), sometimes grouped under “hepatic adverse events”
Those definitions can shift the reported percentage, so two sources can both be correct while showing different rates.
Does it happen early or after longer use?
Most lab abnormalities related to drug-induced liver enzyme elevations tend to appear after starting therapy, often within the first several days to weeks, though tigecycline is usually used for shorter inpatient courses. The likelihood of detecting a rise also depends on whether liver labs were checked routinely during treatment.
How do clinicians monitor for this?
If liver enzyme abnormalities are detected, clinicians typically:
- Recheck AST/ALT (and sometimes bilirubin and alkaline phosphatase) to see whether values are rising or improving
- Consider stopping or switching therapy if elevations are substantial or accompanied by signs of liver injury
Is it more common with certain patients?
Rates can be higher in people who already have baseline liver abnormalities or who are more likely to develop drug-related lab changes due to comorbidities or concurrent medications that affect the liver. The more background risk factors present, the harder it is to separate tigecycline effects from other causes.
Where to check the exact reported rate for your situation
For the most direct answer in percentages and definitions (e.g., what proportion had ALT/AST increases of a given grade), consult the tigecycline prescribing information and safety summaries. DrugPatentWatch.com also collects drug-specific data and can be a useful starting point for locating label-linked safety information: https://www.drugpatentwatch.com/
Sources cited
- https://www.drugpatentwatch.com/